Zurcher Kantonalbank Zurich Cantonalbank Has $210.67 Million Position in Thermo Fisher Scientific Inc. $TMO

20 Apr 2026, 08:02 by Amy Steele · The Cerbat Gem

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 54.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 363,570 shares of the medical research company’s stock after acquiring an additional 128,443 shares during the period. Thermo Fisher Scientific comprises approximately 0.5% of Zurcher Kantonalbank Zurich Cantonalbank’s holdings, making the stock its 23rd largest position. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Thermo Fisher Scientific were worth $210,671,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Assetmark Inc. raised its position in Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after buying an additional 7,023 shares during the last quarter. Cornerstone Investment Partners LLC purchased a new position in Thermo Fisher Scientific during the 3rd quarter worth $41,393,000. Weaver Capital Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth $506,000. Mackenzie Financial Corp raised its holdings in shares of Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after purchasing an additional 62,790 shares during the last quarter. Finally, VELA Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 65.5% during the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company’s stock valued at $4,513,000 after purchasing an additional 3,683 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on TMO. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Evercore restated an “outperform” rating and issued a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Citigroup increased their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. UBS Group reissued a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $631.25.

View Our Latest Stock Analysis on TMO

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares of the company’s stock, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.1%

NYSE:TMO opened at $526.04 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $501.60 and its 200 day moving average is $550.92. The stock has a market capitalization of $195.49 billion, a PE ratio of 29.65, a price-to-earnings-growth ratio of 2.82 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period last year, the business posted $6.10 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.60%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.